Shares of Renalytix Plc (LON:RENX – Get Free Report) were up 14.2% on Monday . The stock traded as high as GBX 2.80 and last traded at GBX 2.65. Approximately 7,356,022 shares were traded during trading, an increase of 719% from the average session volume of 897,943 shares. The stock had previously closed at GBX 2.32.
Renalytix Trading Up 14.2%
The company has a current ratio of 1.21, a quick ratio of 2.42 and a debt-to-equity ratio of -118.57. The company has a 50-day simple moving average of GBX 1.83 and a 200 day simple moving average of GBX 3.37. The firm has a market cap of £11.58 million, a PE ratio of -0.66 and a beta of 1.79.
Renalytix Company Profile
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).
Recommended Stories
- Five stocks we like better than Renalytix
- Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors
- Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains
- This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street
- AI Is Selling Off, But These 5 Stocks Could Benefit Next
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
